Serenex and Aventis sign research agreement

US drug discovery company Serenex has signed a technology evaluation agreement with Aventis Pharmaceuticals, the US subsidiary of French pharmaceutical company Aventis.

This initial agreement gives Aventis the opportunity to evaluate the utility of Serenex's novel chemoproteomics technologies within certain Aventis drug discovery programs as a means to focus on the identification of the best compounds to advance through drug discovery and development.

Under the terms of the agreement, Aventis will supply Serenex with cell lines and sets of small molecules and Serenex will use its high throughput unbiased proteome mining and functional proteome fractionation profiling technologies to rapidly screen these compounds. Information generated by Serenex may be used by Aventis to choose the highest quality molecules to progress through the next stages of drug discovery.